Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
pipeline
Biotech
Alumis pulls back from would-be rival to Amgen’s Tepezza
Alumis is exploring strategic alternatives for its would-be rival to Amgen’s Tepezza, choosing to punt the program rather than enter phase 3.
Nick Paul Taylor
May 15, 2026 3:44am
Takeda 0 for 4 against nausea and vomiting after axing asset
May 13, 2026 5:08am
BeOne shelves 5 cancer programs, halts ph. 2 arthritis trial
May 7, 2026 11:15am
Ipsen scuttles liver disease candidates from Albireo acquisition
May 6, 2026 3:10pm
Recursion's new CEO is bringing the AI outfit back to earth
May 6, 2026 6:30am
Vertex drops Moderna-partnered inhaled CF candidate
May 4, 2026 5:48pm
